The additional morbidities working group has first discussed extensively that we should move away from “complications’ or ‘co-morbidities’ and define the occurrence of disorders that can be related or unrelated to GD as “additional morbidities”. Next, different topics were discussed that could be prioritized. These include, amongst others, malignancies, bone disease, Parkinson’s disease, metabolic syndrome and fatigue.
Hematological and other malignancies
| Hagit Baris Feldman – | Israel |
| Maria Camprodon – | Spain |
| Margaret Giuliani – | IGA |
| Carla Hollak (Chair) – | Netherlands |
| Ivana Kavecan – | Serbia |
| Patricia Lucki – | IGA |
| Eugen Mengel – | Germany |
| David Moreno Martinez – | United Kingdom |
| Uma Ramaswami (Chair) – | United Kingdom |
| Thomas Stulnig – | Austria |
| Neal Weinreb – | United States |
The first project that we focus on is: “Hematological and other malignancies”. We hope to produce a first draft of the consensus document which describes the epidemiology with practical guidelines for surveillance
